News | December 17, 2025
Pfizer cuts 2026 revenue outlook amid COVID-19 & patent losses
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
The company operates a chain of mid-sized multi-speciality hospitals
The upcoming trials will evaluate both active and chronic TED in randomized, double-blind, placebo-controlled studies
The randomized, double-blind, placebo-controlled single ascending dose (SAD) study evaluated safety, tolerability, pharmacokinetics, and target engagement in 46 healthy participants
Imsidolimab, an IgG4 IL-36 receptor antagonist, works by inhibiting IL-36 receptor signaling, directly addressing the deficiency in the IL-36RA regulator common in GPP patients
Ryght AI tackles these hurdles with its AI Site Twin platform
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
Subscribe To Our Newsletter & Stay Updated
